Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$734M |
| 2 |
Adobe
ADBE
|
+$488M |
| 3 |
Merck
MRK
|
+$443M |
| 4 |
Tesla
TSLA
|
+$366M |
| 5 |
AGN
Allergan plc
AGN
|
+$315M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$682M |
| 2 |
Perrigo
PRGO
|
+$585M |
| 3 |
Gilead Sciences
GILD
|
+$556M |
| 4 |
EMC
EMC CORPORATION
EMC
|
+$432M |
| 5 |
Morgan Stanley
MS
|
+$401M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.94% |
| 2 | Consumer Discretionary | 14.99% |
| 3 | Communication Services | 11.27% |
| 4 | Technology | 9.94% |
| 5 | Financials | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FPO
401
DELISTED
First Potomac Realty Trust
FPO
| $29.7M | 0.03% |
2,553,359
-944,923
| -27% | -$11.3M |
|
402
Columbia Banking Systems
COLB
$8.71B
| $28.5M | 0.03% |
1,035,573
+257,557
| +33% | +$6.75M |
|
|
VR
403
DELISTED
Validus Hold Ltd
VR
| $28.4M | 0.03% |
706,139
-27,421
| -4% | -$1.07M |
|
404
Monster Beverage
MNST
$95.1B
| $28.2M | 0.03% |
2,494,560
-9,402,330
| -79% | -$92.4M |
|
|
CMCSK
405
DELISTED
COMCAST CORP SPL A (NEW)
CMCSK
| $28.1M | 0.03% |
562,966
-2,172
| -0.4% | -$108K |
|
|
GAP
406
The Gap Inc
GAP
$7.3B
| $27.8M | 0.03% |
710,902
-284,038
| -29% | -$11.1M |
|
|
EXXI
407
DELISTED
ENERGY XXI LTD COM SHS
EXXI
| $27.8M | 0.03% |
1,025,986
+1,218
| +0.1% | +$34.9K |
|
408
AXIS Capital
AXS
$7.81B
| $27.7M | 0.03% |
582,120
-36,011
| -6% | -$1.7M |
|
|
PTLA
409
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $27.6M | 0.03% |
1,071,080
-7,714
| -0.7% | -$187K |
|
|
IPXL
410
DELISTED
Impax Laboratories, Inc.
IPXL
| $27.5M | 0.03% |
1,095,327
+427,839
| +64% | +$9.54M |
|
|
411
PUT
Gilead Sciences
GILD
$165B
| $27.4M | 0.03% |
365,000
| – | – |
|
|
RPRX
412
DELISTED
Repros Therapeutics Inc.
RPRX
| $27.4M | 0.03% |
1,494,980
+255,732
| +21% | +$4.83M |
|
|
PETX
413
DELISTED
Aratana Therapeutics, Inc.
PETX
| $26.9M | 0.03% |
1,409,136
+979,183
| +228% | +$19.9M |
|
|
XL
414
DELISTED
XL Group Ltd.
XL
| $26.6M | 0.03% |
834,631
-39,277
| -4% | -$1.22M |
|
|
SGMO
415
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $26.5M | 0.03% |
1,907,543
+421,045
| +28% | +$4.85M |
|
416
Kosmos Energy
KOS
$1.47B
| $26.3M | 0.03% |
2,351,215
+2,582
| +0.1% | +$27.6K |
|
417
Kirby Corp
KEX
$7.01B
| $26M | 0.03% |
261,881
-30,179
| -10% | -$2.77M |
|
|
HOLX
418
DELISTED
Hologic
HOLX
| $26M | 0.03% |
1,161,238
-5,893,077
| -84% | -$130M |
|
419
HF Sinclair
DINO
$16.2B
| $25.7M | 0.03% |
517,513
-11,743
| -2% | -$535K |
|
420
PPG Industries
PPG
$24.9B
| $25.6M | 0.03% |
270,004
-9,454
| -3% | -$852K |
|
|
ALTR
421
DELISTED
Altera Corp
ALTR
| $25.4M | 0.02% |
779,527
-2,746
| -0.4% | -$91.9K |
|
|
INN
422
Summit Hotel Properties
INN
$766M
| $25.2M | 0.02% |
2,804,390
-77,576
| -3% | -$698K |
|
423
JB Hunt Transport Services
JBHT
$25.9B
| $24.7M | 0.02% |
319,215
-268,539
| -46% | -$20M |
|
|
RP
424
DELISTED
RealPage, Inc.
RP
| $24.6M | 0.02% |
1,053,515
+668,369
| +174% | +$15.9M |
|
425
Tandem Diabetes Care
TNDM
$1.27B
| $24.3M | 0.02% |
+94,442
| New | +$21.6M |
|
Similar funds
Jennison Associates's Q4 2013 Portfolio in Review
As of Q4 2013, Jennison Associates held 759 positions worth $102B, up 6.9% from $95.4B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q4 2013 filing shows 79 new, 184 increased, 411 reduced and 54 closed positions. Its largest new stake was Allergan plc: 2,016,619 shares worth $339M. The largest sale was UnitedHealth, an estimated $682M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q4 2013 buy was Allergan plc: 2,016,619 shares worth $339M.
- Jennison Associates added most to Bristol-Myers Squibb in Q4 2013, an estimated $734M increase.
- Jennison Associates's biggest Q4 2013 reduction was UnitedHealth, cutting an estimated $682M.
- Jennison Associates fully exited Perrigo in Q4 2013, selling an estimated $585M.
- Jennison Associates's ten largest holdings make up 20% of its $102B portfolio in Q4 2013.
- Jennison Associates opened 79 new positions and closed 54 in Q4 2013.
- Jennison Associates's portfolio value rose 6.9% quarter-over-quarter to $102B.
Based on Jennison Associates's 13F filing for Q4 2013, filed 10 Feb 2014.